• 

  1921

  Heart disease becomes leading cause of death in the United States, according to mortality data collected by the Census Bureau.

• 

  1953

  Surgeons perform first successful open heart surgery using heart-lung machine at Jefferson Medical College in Philadelphia.

• 

  1977

  Dr. Andreas Gruentzig demonstrates utility of percutaneous transluminal angioplasty (PTCA) at University Hospital in Zurich, Switzerland, ushering in the era of interventional cardiology.

• 

  1986

  First self-expanding coronary stents are deployed following coronary angioplasty resulting in lowered restenosis rates, followed three years later by balloon-expandable coronary stents and later by drug-eluting stents, each generation yielding improved outcomes for patients with coronary artery disease.

• 

  2000

  Radio frequency ablation is demonstrated to be a complementary adjunct to conventional cardiac surgery for treatment of atrial fibrillation, jump-starting a new medical specialty; interventional electrophysiology.

• 

  Other successful catheter-based, less-invasive left heart procedures followed, including mitral valve repair and replacement, and appendage closure.

• 

  2010

  MDI Inc. demonstrates a passive, simple-to-use system that isolates all thoracic veins, effectively blocking significant pathways for signals that trigger atrial fibrillation. Additional testing in a controlled study will be designed to demonstrate safety and efficacy.

In 2010, MDI was founded to develop a new technology for treatment of atrial fibrillation (AF) with the goal of bringing a simpler solution to the treatment of this serious condition, estimated to occur in over ten million people worldwide and increasing at about 2% annually.

Based on more than two decades of clinical and device development expertise, MDI has developed a therapy that addresses three fundamental disadvantages of current therapies: complexity of procedure, lengthy procedure time, and high operator skill requirement. Because of limitations of current therapies, we believe the worldwide market is significantly under penetrated with an opportunity for a safe, simple and effective procedure to rapidly expand the served market.

MDI has assembled a strong team of innovative thinkers who are passionate about developing this novel technology with one goal in mind, "Improve the lives of patients through innovation that simplifies a complex and time-consuming procedure."

• Home
• Atrial Fibrillation
• Investor Information
• News
• Our Team
• Careers
• Contact